Roche announces vemurafenib improved survival in people with metastatic melanoma who have BRAF V600 mutations
5 June 2011 | By Roche
Roche announced that a Phase III study (BRIM3) showed vemurafenib (RG7204, PLX4032) significantly improved overall survival in people with previously untreated BRAF V600 mutation...